These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32108991)

  • 1. Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation.
    Fazavana J; Brophy TM; Chion A; Cooke N; Terraube V; Cohen J; Parng C; Pittman D; Cunningham O; Lambert M; O'Donnell JS; O'Sullivan JM
    J Thromb Haemost; 2020 Jun; 18(6):1278-1290. PubMed ID: 32108991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1.
    Chion A; Byrne C; Atiq F; Doherty D; Aguila S; Fazavana J; Lopes P; Karampini E; Amin A; Preston RJS; Baker RI; McKinnon TAJ; Zhu S; Gilbert JC; Emsley J; Jilma B; O'Donnell JS
    Blood; 2024 Sep; 144(13):1445-1456. PubMed ID: 38996211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance.
    Wohner N; Legendre P; Casari C; Christophe OD; Lenting PJ; Denis CV
    J Thromb Haemost; 2015 May; 13(5):815-20. PubMed ID: 25728415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R1205H (Vicenza) causes conformational changes in the von Willebrand factor D'D3 domains and enhances von Willebrand factor binding to clearance receptors LRP1 and SR-AI.
    Atiq F; Rawley O; O'Sullivan JM; Özbil M; Doherty D; Cooke N; Terraube V; Chion A; Amin A; Hulshof AM; Baci B; Byrne C; Aburawi HE; Lillicrap D; O'Donnell JS
    J Thromb Haemost; 2024 Oct; 22(10):2752-2760. PubMed ID: 38996914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor.
    O'Sullivan JM; Aguila S; McRae E; Ward SE; Rawley O; Fallon PG; Brophy TM; Preston RJ; Brady L; Sheils O; Chion A; O'Donnell JS
    J Thromb Haemost; 2016 Dec; 14(12):2446-2457. PubMed ID: 27732771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance.
    Chion A; O'Sullivan JM; Drakeford C; Bergsson G; Dalton N; Aguila S; Ward S; Fallon PG; Brophy TM; Preston RJ; Brady L; Sheils O; Laffan M; McKinnon TA; O'Donnell JS
    Blood; 2016 Oct; 128(15):1959-1968. PubMed ID: 27554083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage LRP1 contributes to the clearance of von Willebrand factor.
    Rastegarlari G; Pegon JN; Casari C; Odouard S; Navarrete AM; Saint-Lu N; van Vlijmen BJ; Legendre P; Christophe OD; Denis CV; Lenting PJ
    Blood; 2012 Mar; 119(9):2126-34. PubMed ID: 22234691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance.
    Ward SE; O'Sullivan JM; Moran AB; Spencer DIR; Gardner RA; Sharma J; Fazavana J; Monopoli M; McKinnon TAJ; Chion A; Haberichter S; O'Donnell JS
    Haematologica; 2022 Mar; 107(3):668-679. PubMed ID: 33763999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.
    Brophy TM; Ward SE; McGimsey TR; Schneppenheim S; Drakeford C; O'Sullivan JM; Chion A; Budde U; O'Donnell JS
    Arterioscler Thromb Vasc Biol; 2017 May; 37(5):845-855. PubMed ID: 28279966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha.
    Martin C; Morales LD; Cruz MA
    J Thromb Haemost; 2007 Jul; 5(7):1363-70. PubMed ID: 17389010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro phosphorylation of von Willebrand factor by FAM20c enhances its ability to support platelet adhesion.
    Da Q; Han H; Valladolid C; Fernández M; Khatlani T; Pradhan S; Nolasco J; Matsunami RK; Engler DA; Cruz MA; Vijayan KV
    J Thromb Haemost; 2019 Jun; 17(6):866-877. PubMed ID: 30864273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
    Tang L; Leong L; Sim D; Ho E; Gu JM; Schneider D; Feldman RI; Monteclaro F; Jiang H; Murphy JE
    Haemophilia; 2013 Jul; 19(4):539-45. PubMed ID: 23534820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding.
    Parker DN; Tasneem S; Farndale RW; Bihan D; Sadler JE; Sebastian S; de Groot PG; Hayward CP
    Thromb Haemost; 2016 Jul; 116(1):87-95. PubMed ID: 27052467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.
    Jenkins PV; Pasi KJ; Perkins SJ
    Blood; 1998 Mar; 91(6):2032-44. PubMed ID: 9490688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.
    Tischer A; Brehm MA; Machha VR; Moon-Tasson L; Benson LM; Nelton KJ; Leger RR; Obser T; Martinez-Vargas M; Whitten ST; Chen D; Pruthi RK; Bergen HR; Cruz MA; Schneppenheim R; Auton M
    J Mol Biol; 2020 Jan; 432(2):305-323. PubMed ID: 31628947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand factor arginine 1205 substitution results in accelerated macrophage-dependent clearance in vivo.
    Rawley O; O'Sullivan JM; Chion A; Keyes S; Lavin M; van Rooijen N; Brophy TM; Fallon P; Preston RJ; O'Donnell JS
    J Thromb Haemost; 2015 May; 13(5):821-6. PubMed ID: 25690668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib.
    Obert B; Houllier A; Meyer D; Girma JP
    Blood; 1999 Mar; 93(6):1959-68. PubMed ID: 10068669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased galactose expression and enhanced clearance in patients with low von Willebrand factor.
    Aguila S; Lavin M; Dalton N; Patmore S; Chion A; Trahan GD; Jones KL; Keenan C; Brophy TM; O'Connell NM; Ryan K; Byrne M; Nolan M; Patel A; Preston RJS; James P; Di Paola J; O'Sullivan JM; O'Donnell JS
    Blood; 2019 Apr; 133(14):1585-1596. PubMed ID: 30770394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mapping of the chloride-binding site in von Willebrand factor (VWF): energetics and conformational effects on the VWF/ADAMTS-13 interaction.
    De Cristofaro R; Peyvandi F; Baronciani L; Palla R; Lavoretano S; Lombardi R; Di Stasio E; Federici AB; Mannucci PM
    J Biol Chem; 2006 Oct; 281(41):30400-11. PubMed ID: 16899464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational stability and domain unfolding of the Von Willebrand factor A domains.
    Auton M; Cruz MA; Moake J
    J Mol Biol; 2007 Feb; 366(3):986-1000. PubMed ID: 17187823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.